Peptides
Receptor Grade IGF-1 LR3 (1mg)
Between 1940 and 1950, the growth hormone somatotropin was identified and researched. It was tentatively suggested that this hormone might enhance sulfate uptake in normal control rat serum, implying an increase in amino acid uptake or synthesis. However, this connection was not definitively established. This so-called "sulfate factor" was subsequently isolated from the rat serum and named "somatomedin." Concurrently, an independent study explored the components responsible for producing insulin-like activity. It was hypothesized during this investigation that these components might be "somatomedins," leading to the designation of these compounds as "insulin-like growth factors."(1) Further explorations into the insulin-like growth factors involved gene-targeting approaches to potentially enhance their bioavailability and potency. During these studies, a variant called Receptor Grade IGF-1 LR3 was developed. This variant included an additional arginine residue and featured an elongated structure at the N-terminal (by 13 amino acids), resulting in a protein composed of 83 amino acids, compared to the 70 amino acids found in natural IGF-1.(1) Receptor Grade IGF-1 LR3 peptide, a polypeptide amino acid also known as Long arginine 3 IGF-1, or LR3-IGF-1, has been suggested to exhibit potential action similar to Insulin-like Growth factor-1, or IGF-1.(2) IGF-1 is a naturally produced protein comprised of 70 amino acids. Structurally similar to insulin, this Receptor Grade IGF-1 LR3 has the potential primarily to regulate cell tissue and development. Several synthetic variations of IGF-1, such as recombinant IGF-1 (rhIGF-1), were developed to mimic the natural protein identically and stimulate similar actions as IGF-1. Another example is Receptor Grade IGF-1 LR3, which researchers speculate exhibits an increased affinity and anabolic potential while binding less to IGF-1 binding proteins (IGF-1BPs). This variant has been developed particularly for evaluation in cell growth studies. Moreover, the designation of Receptor Grade refers to the purity of the material, which is considered higher than Media Grade IGF-1 LR3. Structurally, IGF-1 LR3 contains an extended N-terminal structure and arginine acid at residue 3. Hence, it is named IGF-1 Long R3.(3) Owing to the altered structure, Receptor Grade IGF-1 LR3 has been suggested to bind poorly with IGF-binding proteins, shortening its duration of action. Overview IGF proteins appear to exert potential via binding with IGF-1 receptors; however, researchers posit that these IGF binding proteins, including Receptor Grade IGF-1 LR3, may function either via IGF receptor-dependent mechanism or via IGF-independent mechanisms.(1)(4) A study(1) was conducted where a murine model was exposed to the endogenous IGF-1 with IGF-1 LR3. During this study, it was suggested that upon exposure, the synthetic protein exhibited the potential to quickly clear the serum and distribute into tissues. Increased concentrations of the IGF-1 LR3 tracer were apparently detected in specific organs, including the kidneys, ovaries, and adrenal glands, in mouse models. This distribution pattern indicates that organs critical to metabolism and reproductive processes might have differing abilities to absorb or retain IGF-1 LR3 compared to IGF-I. It is proposed that these variations might arise due to IGF-1 LR3's reduced tendency to bind with IGFBPs. IGFBPs are proteins that regulate the availability of IGFs in circulation, influencing their interaction with various tissues. The decreased binding of IGF-1 LR3 to IGFBPs may affect its bioavailability and interactions with specific tissues in research settings. Researchers suggest Receptor Grade IGF-1 LR3 has the potential to induce a signaling mechanism in the organism, either via autocrine mode (where the tissue cell stimulates itself) or via paracrine mode (where the tissue cell stimulates the nearby cell). The increased potential bioavailability of these autocrine and paracrine IGF-1 LR3 proteins may prove vital to inducing any possible action. Chemical Makeup Molecular Formula: C400H625N111O115S9 Molecular Weight: 9117.5 g/mol Other Known Titles: Long-(arg3) insulin-like growth factor-I, Insulin-like growth factor long chain R3 Research and Clinical Studies Receptor Grade IGF-1 LR3 Peptide and Tissue Anabolism The body of research examining the anabolic capabilities of IGF-1 LR3 remains insufficient, primarily because this peptide is designed for evaluation in cell culture studies. However, limited studies using murine models hint at a considerable anabolic potential of IGF-1 LR3. In particular, one investigation involved normal and dexamethasone-induced catabolic murine models.(3) The researchers commented that “LR3IGF-I, were approx. 2.5-fold more potent than IGF-I” in promoting anabolic observations. These included weight gain, increased weight of visceral organs, and potentially improved feed efficiency when the murine models were exposed to it continuously. Another observation from studies on murine models exposed to catabolic agents revealed a reduction in the excretion of Nτ-methylhistidine, a marker of muscle protein degradation, which was notably more pronounced with IGF-1 LR3—potentially three times greater than with IGF-I. These observations indicate that IGF-1 LR3 may exhibit superior anabolic actions under specific experimental conditions, although this is not uniformly seen across all measured parameters. Therefore, it is conceivable that Receptor Grade IGF-1 LR3 may manifest an even greater anabolic capacity than IGF-1, according to multiple comparative studies on the anabolic properties of IGF-1. For example, there is a 2005 clinical study(6) where the action of rhIGF-1 on models of IGF-1 deficiency and growth disorders was studied. RhIGF-1 is the recombinant form of insulin-like growth factor-1, and has been researched for its potential in mitigating growth hormone (GH) insensitivity. RhIGF-1 is a synthetic form of IGF-1.(11) Research models of GH deficiencies were examined in the course of this controlled study, where rhIGF-1 was presented once daily to all the models. The heights and lengths were measured before and after the study. Researchers suggested that results indicated an average increase in height by 7cm per year in all subjects presented with rhIGF-1. Hence, this study posits that IGF-1 analogs may have a positive potential within the context of growth hormone deficiency research. Receptor Grade IGF-1 LR3 and Metabolic Activity Studies(7) have suggested that IGF-binding proteins, including Receptor Grade IGF-1 LR3, may have the potential to induce glucose uptake and, thereby, glucose metabolism through the possible activation of signaling mechanisms. Namely, this may have occurred through a signaling mechanism involving PI3K and AMPK pathways. For example, it can be hypothesized that upon binding to their respective receptors, IGF-1 analogs potentially trigger a cascade of biochemical events involving the PI3K pathway. This pathway, integral to cellular growth and survival, might also play a pivotal role in mediating the actions of IGF-1 on glucose uptake. Activation of PI3K might lead to the stimulation of protein kinase B (Akt), a key regulator in the pathway, enhancing glucose transporter translocation to the cell membrane and increasing glucose uptake. Concurrently, the AMPK pathway, studied for its potential in energy balance and metabolism regulation, may be indirectly influenced by IGF-1 analogs. It is conceivable that the modulation of AMPK activity by these analogs may enhance cellular glucose uptake under energy stress conditions. This activation potentially promotes the translocation of GLUT4, a major glucose transporter, to the cell surface, thus facilitating glucose entry into cells. Receptor Grade IGF-1 LR3 and Muscle This study(8) was conducted on female mice to examine the action of Receptor Grade IGF-1 LR3 on reducing myostatin. Myostatin is a muscle protein that primarily prevents muscle cell differentiation and growth. Reducing the action of myostatin may potentially increase lean muscle mass and reduce fat mass. In this study(8) it was suggested that different IGF-1 analogs, including IGF-1 LR3, have the potential to counteract the negative action of myostatin protein, possibly helping to prevent apoptosis and protecting muscle cells. Since Receptor Grade IGF-1 LR3 has an apparently longer half-life than IGF-1 (according to the researchers), the potential action of Receptor Grade IGF-1 LR3 was considered. Receptor Grade IGF-1 LR3 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Yakar, S et al., 40 YEARS OF IGF1: Insulin-like growth factors: actions on the skeleton (Jul 2018). Journal of Molecular Endocrinology, vol. 61 Issue 1. https://doi.org/10.1530/JME-17-0298 Growth hormone, athletic performance, and aging. Harvard Health Publishing, Harvard Medical School. https://www.health.harvard.edu/diseases-and-conditions/growth-hormone-athletic-performance-and-aging Tomas, F. M., Knowles, S. E., Owens, P. C., Chandler, C. S., Francis, G. L., Read, L. C., & Ballard, F. J. (1992). Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. The Biochemical journal, 282 ( Pt 1)(Pt 1), 91–97. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1130894/ Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol. 2002 Oct;175(1):19-31. https://pubmed.ncbi.nlm.nih.gov/12379487/ Anderson, L. J., Tamayose, J. M., & Garcia, J. M. (2018). Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects. Molecular and cellular endocrinology, 464, 65–74. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723243/ IGF1 Deficiency, Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated with IGF-1 Deficiency. https://clinicaltrials.gov/ct2/show/NCT00125190?cond=IGF1+Deficiency Assefa, B., Mahmoud, A. M., Pfeiffer, A., Birkenfeld, A. L., Spranger, J., & Arafat, A. M. (2017). Insulin-Like Growth Factor (IGF) Binding Protein-2, Independently of IGF-1, Induces GLUT-4 Translocation and Glucose Uptake in 3T3-L1 Adipocytes. Oxidative medicine and cellular longevity, 2017 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750484/ Naisi Li, Qiyuan Yang, Ryan G. Walker, Thomas B. Thompson, Min Du, Buel D. Rodgers, Myostatin Attenuation In Vivo Reduces Adiposity, but Activates Adipogenesis, Endocrinology, Volume 157, Issue 1, 1 January 2016, Pages 282–291. https://doi.org/10.1210/en.2015-1546 William E. Sonntag, Anna Csiszar, Raphael de Cabo, Luigi Ferrucci, Zoltan Ungvari, Diverse Roles of Growth Hormone and Insulin-Like Growth Factor-1 in Mammalian Aging: Progress and Controversies, The Journals of Gerontology: Series A, Volume 67A, Issue 6, June 2012, Pages 587–598, https://doi.org/10.1093/gerona/gls115 Mario Thevis (13 December 2010). Mass Spectrometry in Sports Drug Testing: Characterization of Prohibited Substances and Doping Control Analytical Assays. John Wiley & Sons. pp. 252. https://books.google.ca/books?id=dWHQMev5mHwC&pg=PA252& Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Ad Ther. 2009 Jan; 26(1):40-54. https://pubmed.ncbi.nlm.nih.gov/19198769/ Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Kisspeptin-10 (10mg)
Kisspeptin-10 is a naturally occurring peptide protein encoded by the KISS1 gene.(2) Kisspeptin is a product of the KISS1 gene, produced by the cleavage of the original 145-amino acid polypeptide to a smaller peptide. This smaller peptide, composed of 54-amino acids, is cleaved further to become Kisspeptin 45-54, also known as Kisspeptin 10.(6) KISS1 is a gene that is considered to suppress metastases of melanomas and breast carcinomas, thereby inhibiting abnormal cell growth and potentially preventing cancer.(2) Initially considered to be a metastasis suppressor, Kisspeptin-10 was later suggested to possess a different expression profile, which may potentially allow it to function on the hypothalamus and pituitary gland, thereby impacting the reproductive system.(3) Several independent studies in the mid-2000s suggested that Kisspeptin-10 may play a role in hypogonadotropic hypogonadism, as the peptide is considered to be a ligand of the G-protein coupled receptor 54 (GPR54).(5) Research continues to explore this potential aspect of the Kisspeptin-10 peptide. Hypogonadism is a system disorder wherein reproductive organs produce less or no sex hormones. One of the forms of hypogonadism is called hypogonadotropic hypogonadism, where the organism suffers from hypogonadism due to under-functioning of the pituitary gland or hypothalamus.(1) GnRH is considered to stimulate the pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Both FSH and LH are considered to regulate reproductive function.(1) Lack of these hormones, i.e. GnRH, FSH, and LH, are considered the main factors of hypogonadotropic hypogonadism. Overview GPR54, also called the KISS1 receptor (KISS1R),(7) has been suggested by researchers to be an important GnRH receptor.(1) They further suggest that Kisspeptin-10 exhibits action by possibly binding to GPR54 receptors, which may activate the reproductive axis by stimulating the release of GnRH and gonadotropin neurons.(7) Kisspeptin-10 is a 54 amino acid peptide which is considered to be a product of the KISS1 gene. Researchers have isolated smaller peptide fragments such as Kisspeptin 10, 13, and 14, which all have been suggested to possess some biological activity towards GPR54.(7) These smaller peptides have been posited to bind with a low affinity to the GPR54 receptors and possibly stimulate calcium mobilization, arachidonic acid release, and extracellular protein kinase phosphorylation.(7) These events may depolarize the Kisspeptin-10 neurons, possibly leading to the depolarization of the GnRH neurons and modulating gonadotropin release, to some extent.(9) Research studies on Kisspeptin-10 have explored its potential in a wide variety of functions and impacts, and several hypotheses have been presented on the peptide's possible mechanisms of action, including some notable hypotheses below:(8) That the Kisspeptin-10 peptide may potentially stimulate GnRH release; The peptide may potentially stimulate endogenous gonadotropin release in less-fertile animal models; Peptide concentrations may possibly induce desensitization and suppression of the hypothalamus, pituitary gland, and gonadal axis. Chemical Makeup Molecular Formula: C63H83N17O14 Molecular Weight: 1302.4 g/mol Other Known Titles: Kisspeptin 45-54 Research and Clinical Studies Kisspeptin-10 and Reproduction As part of one 2017 study,(10) a literature review was conducted for all articles published from 1999 to 2016. Upon review of the articles, it was suggested that experimental data may support the hypothesis that the Kisspeptin-10 system (including the KISS1 gene and its products, GPR54 receptors) may possibly regulate the release of gonadotropin hormones. Furthermore, certain studies were conducted in experimental animal models with similar characteristics as hypogonadotropic hypogonadism (HH) and polycystic ovarian syndrome (PCOS). These studies suggested that reproductive disorders such as HH and PCOS may occur due to abnormalities in the KISS1 and GPR54 system. The outcome of this literature review suggested that Kisspeptin-10 may be a neuropeptide regulator of GnRH release. Kisspeptin-10 and Delayed Hormonal Development The main goal of this study(13) was to evaluate the potential of Kisspeptin-10 peptide in research models of stunted development. Researchers hypothesized that the peptide might stimulate the gonadal hormonal release and regulate the reproductive system in the experimental models. The study randomly introduced either Kisspeptin-10 or gonadotropin-releasing hormone (GnRH). The levels of luteinizing hormone (LH) were monitored overnight. All research models were then exposed to GnRH for 6 days, then evaluated for LH levels. A total 47% of the experimental group exhibited positive impacts as a possible result of Kisspeptin-10 presence, with increased levels of LH hormone. An additional 6% of the group exhibited an intermediate response, and the remaining 47% exhibited no response as a result of peptide exposure. Kisspeptin-10 and Emotional Modulation The main purpose of this study(14) was to understand the potential of Kisspeptin-10 on limbic brain activity. Following Kisspeptin-10 exposure in the research models, results were monitored via neuroimaging and psychometric analysis. The data from the study suggested that the peptide appeared to have led to some enhanced limbic brain activity. The models appeared to exhibit an increased response towards sexual and bonding stimuli. Kisspeptin-10 and Reproductive Hormone Release The key objective of this study(15) was to establish the potential of Kisspeptin-10 on reproductive hormone release. Kisspeptin-10 was presented to both male and female experimental models. Results in the males indicated that the levels of FSH and LH were increased following peptide exposure. In the females, no alterations were reported in the levels of LH and FSH during the menstrual cycle. However, during the preovulatory phase, the levels of FSH and LH were reportedly elevated. Kisspeptin-10 and Food Intake Kisspeptin-10 is considered to be widely distributed in brain sites, including the hippocampus, cerebellum, posterior hypothalamus, and septum. Owing to its apparently vast distribution and presence in the food intake regulating nuclei, such as Arc, found in the hypothalamus, this study(11) was conducted to examine the potential impact of Kisspeptin-10 on food intake. This experiment was conducted on adult male mice aged between 6 and 8 weeks, caged under normal temperatures and conditions. These mice were subjected to a standard rodent diet and tap water. Overnight fasted mice and the experimentally fed mice were presented with different concentrations of Kisspeptin-10 or placebo. Results suggested that the peptide in the overnight fasted mice may have decreased food intake during the first 3-to-12-hour period. The food intake then reportedly increased during the 12-to-16-hour period, resulting in a similar food intake compared to the placebo group. This result suggested that the peptide led to a decrease in meal frequency and total meal time and increased intervals between meals. However, meal size and eating rate were almost similar to that of the placebo mice. To delve deeper into the subject, researchers have undertaken studies to investigate the potential actions of Kisspeptin-10 on food intake by examining the apparent influence of the peptide on appetite regulation in the central nervous system. The scientists suggested that the peptide may have some influence on the expression of genes related to neuropeptide Y (NPY) and brain-derived neurotrophic factor (BDNF). It has also been posited to have a potential impact on the concentrations of dopamine, norepinephrine, serotonin (also known as 5-hydroxytryptamine or 5-HT), dihydroxyphenylacetic acid, and 5-hydroxyindoleacetic acid within hypothalamic cells (specifically Hypo-E22 cells). Findings indicate that Hypo-E22 cells might be receptive to Kisspeptin-10, which may potentially elevate NPY gene expression. Conversely, it appeared to suppress the expression of BDNF. Furthermore, Kisspeptin-10 may have reduced serotonin and dopamine concentrations, though norepinephrine levels seemed to remain stable. This reduction in dopamine and serotonin was reflected by an increase in the ratios of their metabolites, dihydroxyphenylacetic acid to dopamine and 5-hydroxyindoleacetic acid to serotonin, respectively, following exposition to the peptide. The observed enhancement in NPY gene expression, alongside the diminution of BDNF expression and serotonin activity, may suggest the hunger-influencing potential of Kisspeptin-10.(12) Studies in Impaired Kisspeptin-10 Systems As part of this study,(13) the energetic and metabolic potential of Kisspeptin-10 was compared between control mice and mice with impaired Kisspeptin systems. Results suggested that female mice with impaired Kisspeptin systems exhibited dramatic increases in body weight and significantly impaired glucose tolerance levels. While the peptide exposed and impaired female mice ate less than the control female mice, they were more obese, with reduced locomotor activity and respiratory rate. No reported difference was found between control male mice and male mice with impaired Kisspeptin systems. Both exhibited normal body weight and glucose levels. Kisspeptin-10 and Neuroprotection The accumulation of amyloid-beta (Aβ) and alpha-synuclein (α-syn) within cholinergic neurons is believed to damage and potentially cause dysfunction within important central nervous system structures. However, it has been proposed that Kisspeptin-10 may attach to Aβ on the outside of cells, which may, in turn, possibly reduce the harmful actions of Aβ.(16) Studies have suggested that Kisspeptin-10 peptides may counteract the damaging actions of Aβ, prion protein (PrP), and Islet Amyloid Polypeptide (IAPP) without being hindered by the antagonists of the kisspeptin receptor (GPR-54) or the neuropeptide FF (NPFF) receptor. Given the resemblance between the non-amyloid-β component (NAC) of α-syn and the C-terminus of Aβ, it has been speculated that Kisspeptin-10 might also lessen the toxicity caused by α-syn in cholinergic neurons.(17) Research involving cholinergic cells has indicated that while high concentrations of Kisspeptin-10 may increase toxicity, lower concentrations may potentially decrease the toxicity induced by both the wild-type and the E46K mutant forms of α-syn. Computational studies have supported these observations by suggesting a potentially actionable interaction between Kisspeptin-10 and the C-terminal residues of α-syn. The molecular dynamics simulations indicated that the complexes formed between Kisspeptin-10 and α-syn appeared to have demonstrated good stability. Researchers have also delved into investigating whether the activation of GPR54 (the receptor for the Kisspeptin gene) is crucial for the potential of Kisspeptin-10 to bind to the C-terminal pockets of α-syn. In one study, ChAT-positive SH-SY5Y neurons were genetically modified to produce either the wild-type or the E46K mutant version of α-syn, and the actions of Kisspeptin-10 on the neuronal damage caused by α-syn were assessed through flow cytometry and immunocytochemistry methods.(18) Results suggested that Kisspeptin-10 may have lessened both apoptosis and mitochondrial damage in cholinergic neurons affected by either form of α-syn. Notably, the seeming protective action of Kisspeptin-10 did not appear to be impacted when introduced alongside a GPR54 antagonist, kisspeptin-234 (KP-234), implying that the activation of GPR54 may not be necessary for the actions of Kisspeptin-10. Additionally, it was observed that Kisspeptin-10 may have reduced the presence of α-syn and choline acetyltransferase (ChAT) in neurons that overexpressed the wild-type and E46K mutant α-syn, further highlighting its potential neuroprotective capacity. Kisspeptin-10 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Hypogonadotropic hypogonadism. US National Library of Medicine. https://medlineplus.gov/ency/article/000390.htm KISS1 KiSS-1 metastasis suppressor [Homo sapiens (humans)]. https://www.ncbi.nlm.nih.gov/gene/3814 Hussain, Mehboob A et al. “There is Kisspeptin - And Then There is Kisspeptin.” Trends in endocrinology and metabolism: TEM vol. 26,10 (2015): 564-572. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587393/ Pasquier, J., Kamech, N., Lafont, A., Vaudry, H., Rousseau, K., & Dufour, S. (2014). MOLECULAR EVOLUTION OF GPCRS: Kisspeptin/kisspeptin receptors, Journal of Molecular Endocrinology, 52(3), T101-T117. https://jme.bioscientifica.com/view/journals/jme/52/3/T101.xml Messager, S., Chatzidaki, E. E., Ma, D., Hendrick, A. G., Zahn, D., Dixon, J., Thresher, R. R., Malinge, I., Lomet, D., Carlton, M. B., Colledge, W. H., Caraty, A., & Aparicio, S. A. (2005). Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. Proceedings of the National Academy of Sciences of the United States of America, 102(5), 1761–1766. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545088/ Mead, E. J., Maguire, J. J., Kuc, R. E., & Davenport, A. P. (2007). Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. British journal of pharmacology, 151(8), 1143–1153. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189831/ Rønnekleiv, O. K., & Kelly, M. J. (2013). Kisspeptin excitation of GnRH neurons. Advances in experimental medicine and biology, 784, 113–131. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019505/ Prague JK, Dhillo WS. Potential Clinical Use of Kisspeptin. Neuroendocrinology. 2015;102(3):238-45. doi: 10.1159/000439133. Epub 2015 Aug 7. https://pubmed.ncbi.nlm.nih.gov/26277870/ Tng E. L. (2015). Kisspeptin signalling and its roles in humans. Singapore medical journal, 56(12), 649–656. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678402/ Zeydabadi Nejad, S., Ramezani Tehrani, F., & Zadeh-Vakili, A. (2017). The Role of Kisspeptin in Female Reproduction. International journal of endocrinology and metabolism, 15(3), e44337. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702467/ Stengel, A., Wang, L., Goebel-Stengel, M., & Taché, Y. (2011). Centrally injected kisspeptin reduces food intake by increasing meal intervals in mice. Neuroreport, 22(5), 253–257. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063509/ Orlando G, Leone S, Ferrante C, Chiavaroli A, Mollica A, Stefanucci A, Macedonio G, Dimmito MP, Leporini L, Menghini L, Brunetti L, Recinella L. Effects of Kisspeptin-10 on Hypothalamic Neuropeptides and Neurotransmitters Involved in Appetite Control. Molecules. 2018 Nov 24;23(12):3071. doi: 10.3390/molecules23123071. PMID: 30477219; PMCID: PMC6321454. Kristen P. Tolson et.al, Impaired kisspeptin signaling decreases metabolism and promotes glucose intolerance and obesity. The Journal of Clinical Investigation. Published June 17, 2014. https://www.jci.org/articles/view/71075 Chan, Y. M., Lippincott, M. F., Kusa, T. O., & Seminara, S. B. (2018). Divergent responses to kisspeptin in children with delayed puberty. JCI insight, 3(8), e99109. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931121/ Comninos, A. N., Wall, M. B., Demetriou, L., Shah, A. J., Clarke, S. A., Narayanaswamy, S., Nesbitt, A., Izzi-Engbeaya, C., Prague, J. K., Abbara, A., Ratnasabapathy, R., Salem, V., Nijher, G. M., Jayasena, C. N., Tanner, M., Bassett, P., Mehta, A., Rabiner, E. A., Hönigsperger, C., Silva, M. R., Dhillo, W. S. (2017). Kisspeptin modulates sexual and emotional brain processing in humans. The Journal of clinical investigation, 127(2), 709–719. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5272173/ Milton NG, Chilumuri A, Rocha-Ferreira E, Nercessian AN, Ashioti M. Kisspeptin prevention of amyloid-β peptide neurotoxicity in vitro. ACS Chem Neurosci. 2012 Sep 19;3(9):706-19. doi: 10.1021/cn300045d. Epub 2012 May 30. PMID: 23019497; PMCID: PMC3447396. Simon, C., Soga, T., Ahemad, N., Bhuvanendran, S., & Parhar, I. (2022). Kisspeptin-10 Rescues Cholinergic Differentiated SHSY-5Y Cells from α-Synuclein-Induced Toxicity In Vitro. International journal of molecular sciences, 23(9), 5193. https://doi.org/10.3390/ijms23095193 Simon, C., Soga, T., & Parhar, I. (2023). Kisspeptin-10 Mitigates α-Synuclein-Mediated Mitochondrial Apoptosis in SH-SY5Y-Derived Neurons via a Kisspeptin Receptor-Independent Manner. International journal of molecular sciences, 24(7), 6056. https://doi.org/10.3390/ijms24076056 Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Palmitoyl Tetrapeptide-7 (200mg)
Palmitoyl Tetrapeptide-7 is a small peptide composed of four amino acids: palmitoyl, glycine, glutamine, and arginine.(1) It is a synthetic peptide analog of the natural matrikine peptide, which is considered to play a vital role in regulating extracellular matrix (ECM) turnover and other related cellular activities. Initial research suggests that the Palmitoyl Tetrapeptide-7 peptide may stimulate the synthesis of ECM components, such as collagen and elastin, and may inhibit the production of pro-inflammatory cytokines. It has also been hypothesized to modulate gene expression involved in ECM remodeling, cell proliferation, and inflammation.(2) Moreover, Palmitoyl Tetrapeptide-7 may function by suppressing the activity of interleukin-6 (IL-6), a pro-inflammatory cytokine that plays a role in the apoptosis of skin cells (cell aging and death) and inflammation. IL-6 secretion is considered to increase with time, leading to the degradation of the ECM, and resulting in a loss of flexibility and structural integrity in the skin barrier. Chemical Makeup(1) Molecular Formula: C34H62N8O7 Molecular Weight: 694.9 g/mol Other Known Titles: Pal-Gly-Gln-Pro-Arg-OH, N-Palmitoylrigin , Palmitoyl-GQPR, Rigin Research and Clinical Studies Palmitoyl Tetrapeptide-7 Mechanism of Action Based on animal studies, Palmitoyl Tetrapeptide-7 has been suggested to potentially inhibit the activity of matrix metalloproteinases (MMPs) in animal models.(3) MMPs are a group of enzymes that may degrade ECM proteins during normal tissue growth. By downregulating MMP activity, Palmitoyl Tetrapeptide-7 may prevent ECM damage and may allow cells to restore and maintain the ECM. More specifically, the peptide might stimulate the production of key components of the skin's extracellular matrix, such as laminin IV and V as well as collagen VII. Laminins may be essential for the structural stability and integrity of the basement membrane, while collagen VII is considered critical in anchoring fibrils that connect the dermis to the epidermis. By potentially enhancing the production of these molecules, Palmitoyl Tetrapeptide-7 might contribute to the maintenance and repair of the skin barrier, thereby improving skin tissue resilience. The peptide is also thought to potentially decrease IL-6 secretion, a cytokine that is believed to play a pivotal role in promoting inflammation. By possibly reducing the levels of IL-6, Palmitoyl Tetrapeptide-7 may act to diminish inflammation, particularly following UVB exposure, which is considered to trigger inflammatory responses in the skin.(4) Palmitoyl Tetrapeptide-7 and Oral Conditions Given the inhibitory potential of the peptide on matrix metalloproteinases (MMPs), research teams have thought to examine the potential action of Palmitoyl Tetrapeptide-7 in mitigating the symptoms of certain oral conditions. MMPs enzymes may break down extracellular matrix (ECM) proteins, including those in the oral cavity. While these enzymes are considered to play a role in various physiological and pathological processes, including tissue repair, wound healing, and inflammation, excessive MMP activity might result in tissue damage and may cause various oral diseases, such as periodontitis, caries, and oral cancer. Studies have also suggested that MMP activity may be upregulated in some oral conditions, including periodontitis, characterized by the destruction of periodontal tissues. The possible inhibition of MMP activity by Palmitoyl Tetrapeptide-7 might potentially prevent or slow the progression of periodontitis (and other oral ailments) by preserving the integrity of the ECM.(3) Palmitoyl Tetrapeptide-7 and Skin Damage Studies suggest that the peptide may stimulate the synthesis of collagen, a key component of the extracellular matrix in the skin, and may produce anti-inflammatory action, which might reduce damage caused by environmental factors such as UV radiation and pollution. Research has suggested that combining Palmitoyl Tetrapeptide-7 with Palmitoyl Oligopeptide (Matrixyl 3000) may synergistically stimulate collagen production and reduce inflammation. This synergy, which the study describes as "dramatic," may help improve skin texture and reduce the depth and length of wrinkling that may occur along the stratum corneum of the epidermal barrier.(5) According to the studies, “Matrixyl 3000 is a synergistic combination of two skin-active peptides, Palmitoyl oligopeptide and Palmitoyl-tetrapeptide-7, which appears promising based on the preliminary data from the manufacturer… However, it remains to be proven effective by independent published clinical studies.” As discussed, Palmitoyl Tetrapeptide-7 may be particularly targeting stimulation of collagen type VII.(4) Collagen type VII is posited to be a vital component of the skin tissues' architecture, primarily contributing to the stability and structural integrity of the dermal-epidermal junction. It is thought to play a key role in anchoring fibrils that connect the outer epidermis to the deeper dermis. This specific collagen might form a crucial part of the basement membrane, potentially serving as a scaffold that maintains the structural cohesion between these skin layers. The presence and functionality of collagen type VII are considered essential for the prevention of blistering disorders, which occur when there is a breakdown in this connection between the dermis and epidermis. Moreover, collagen type VII may also play a role in skin tissue healing. This type of collagen could be critical in skin recovery and repair by possibly facilitating the reattachment of the epidermis to the underlying tissue after an injury. It is posited that enhancing the synthesis of collagen VII might improve wound healing outcomes, particularly in environments compromised by age or dermal afflictions. Palmitoyl Tetrapeptide-7 and Wrinkle Depth The peptide, sometimes classified as an “anti-aging” compound, is so named due to its perceived potential action and enhancement of integral protein production within the skin, as discussed above. In a randomized, double-blind, placebo-controlled clinical study, 20 research models were presented with a cream containing Palmitoyl Tetrapeptide-7 for 12 weeks. The cream was applied twice daily to observable wrinkles along the skin. At the end of the study period, the researchers reported that the cream containing Palmitoyl Tetrapeptide-7 appeared to have reduced the depth and length of the wrinkles compared to the placebo cream.(6) The researchers also observed an apparently significant increase in skin elasticity in the group that received the Palmitoyl Tetrapeptide-7 cream. In another study, 20 research models were exposed to the peptide compound twice a day for four weeks, and instrumental measurements were taken to assess the improvement of biomarkers of cell aging and ECM decline. The study reported an apparent reduction in fine wrinkles by 5.97% after two weeks and 14.07% after four weeks, and a reported increase in skin elasticity by 6.81% after two weeks, and 8.79% after four weeks. Dermal density was reportedly increased by 16.74% after two weeks, and 27.63% after four weeks.(7) Palmitoyl Tetrapeptide-7 is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 10078408, Palmitoyl tetrapeptide-7. Mondon P, Hillion M, Peschard O, Andre N, Marchand T, Doridot E, Feuilloley MG, Pionneau C, Chardonnet S. Evaluation of dermal extracellular matrix and epidermal-dermal junction modifications using matrix-assisted laser desorption/ionization mass spectrometric imaging, in vivo reflectance confocal microscopy, echography, and histology: effect of age and peptide applications. J Cosmet Dermatol. 2015 Jun;14(2):152-60. doi: 10.1111/jocd.12135. Epub 2015 Mar 27. PMID: 25817264. https://pubmed.ncbi.nlm.nih.gov/25817264/ Sorsa T, Tjäderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis. 2004 Nov;10(6):311-8. doi: 10.1111/j.1601-0825.2004.01038.x. PMID: 15533204. https://pubmed.ncbi.nlm.nih.gov/15533204/ Resende, Diana I S P et al. “Usage of Synthetic Peptides in Cosmetics for Sensitive Skin.” Pharmaceuticals (Basel, Switzerland) vol. 14,8 702. 21 Jul. 2021, doi:10.3390/ph14080702 Matrixyl 3000 (palmitoyl oligopeptide & palmitoyl tetrapeptide-7): Back to the future of skin care. Marta Salvador-Ferreira et al. Trending Anti-Aging Peptides. MDPI Journal, Vol 7, Issue 4. https://www.mdpi.com/2079-9284/7/4/91 Hahn Hyung Jin et al. Instrumental evaluation of anti‑aging effects of cosmetic formulations containing palmitoyl peptides, Silybum marianum seed oil, vitamin E and other functional ingredients on aged human skin, Experimental and Therapeutic Medicine, Jun 2016. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
AICAR (50mg)
AICAR is an analog of adenosine monophosphate (AMP), a nucleotide that is considered to play an important role in cellular energy metabolism. It has been studied for its potential applications in research, particularly in reducing reperfusion injury after tissue ischemia and mitigating metabolic disorders. AICAR has been suggested to exert this potential by apparently activating AMP-activated protein kinase (AMPK), an enzyme that regulates various metabolic processes. AMPK potentially plays a role in restoring energy balance. It might do this by inhibiting anabolic processes: energy-consuming pathways like protein and fatty acid synthesis. Simultaneously, it might activate catabolic processes, such as the breakdown of glucose and fats, which generate ATP, thereby increasing the energy supply. There is also a possibility that AMPK influences various other cellular processes, including autophagy (the process by which cells clean out damaged components), mitochondrial biogenesis (the creation of new mitochondria), and the regulation of inflammation and stress responses. This broad range of actions suggests that AMPK might be involved in regulating several aspects of cellular and organismal function. By potentially activating AMPK, AICAR is posited to possibly increase glucose uptake in skeletal muscle, enhance insulin sensitivity, and improve glucose tolerance. AICAR has also been suggested by researchers to have anti-inflammatory potential and may improve physical performance in certain experimental models. Chemical Makeup Molecular formula: C9H15N4O8P Molecular Weight: 338.21 g/mol Other known titles: AICA ribonucleotide Research and Clinical Studies AICAR Peptide and Tissue Protection AICAR may have organ-protective potential, especially against ischemia and reperfusion injury. The nucleotide has been suggested to potentially reduce myocardial infarction size and improve cardiac function in an animal model of myocardial ischemia-reperfusion injury.(1) One meta-analysis aimed to investigate the potential of AICAR on cardiovascular tissues.(2) The data was collected from 5 randomized, placebo-controlled, double-blind clinical studies. From the results, AICAR was suggested to reduce myocardial tissue infarction size and cardiac cell death and apparently improve the overall outcome of the experiment. The study concluded that AICAR may "reduce [...] adverse cardiovascular outcomes." Researchers posited that the apparent protective potential of AICAR may be due to its action on cellular metabolism. AICAR may potentially alter it to become more resistant to lack of oxygen by apparently upregulating the availability of energy that can be used even in anaerobic conditions. One such process is the apparent increase in the availability of myocardial glucose. To achieve that, AICAR may promote myocardial glycogenolysis (glycogen degradation) by activating AMPK. This was suggested by experiments using isolated hearts from halothane-anesthetized murine models. In these studies, AICAR appeared to increase glycogenolysis in the myocardium of murine models, while its action on glycogen synthesis was reportedly negligible. This observation hints at a potential role for AMPK activation in glycogenolysis. Further, AICAR was noted to potentially increase myocardial levels of 5-aminoimidazole-4-carboxamide 1-beta-d-ribofuranotide (ZMP), which is AICAR's active intracellular form. However, there was no apparent change in the activity of glycogen synthase (GS) and glycogen phosphorylase (GP) in tissue homogenates, nor did AICAR seem to affect the levels of glucose-6-phosphate and adenine nucleotides in freeze-clamped tissues of these murine models. These findings suggest the possibility that ZMP might allosterically activate GP, leading to glycogenolysis in the intact hearts of the murine models, thereby providing glucose that can be used for energy even in less optimal conditions for the cells.(3) AICAR may have protective action in other tissues as well. One study investigated the potential of AICAR, an AMPK activator, on an experimental murine model of ethanol-induced hepatic steatosis.(4) The study observed that chronic ethanol exposure appeared to result in a histologically and biochemically fatty liver. Upon AICAR presentation, it appeared to attenuate the degree of change in the liver tissues. AICAR was also posited to decrease the hepatic sterol regulatory element-binding protein 1c (SREBP-1c) and reduce fatty acid synthase (FAS) enzyme expression, reducing triglyceride synthesis in murine models’ livers. SREBP-1c is posited to be a protein apparently involved in lipid metabolism, primarily in liver tissues. It is a member of the SREBP family, which appears to be transcription factors that regulate the expression of genes required to synthesize cholesterol, fatty acids, and triglycerides. Therefore, it is possible that a decrease in SREBP-1c might lead to a reduction in fatty acid synthesis. FAS is an enzyme that is considered to play a crucial role in synthesizing fatty acids. It is suggested to play a role in the process of converting acetyl-CoA and malonyl-CoA, small molecules, into palmitate, a long-chain saturated fatty acid. FAS expression also appears to be regulated by SREBP-1c. AICAR Peptide and Insulin Sensitivity Studies suggest that AICAR may have the potential to improve the insulin sensitivity of various tissues due to its potential to activate the AMPK inside cells and make them draw in glucose. One experimental model aimed to investigate whether AICAR could potentially enhance glucose transport in equine skeletal muscle.(5) Upon presentation, AICAR appeared to decrease glucose and increase insulin concentration without affecting lactate concentration. AICAR was also observed to potentially increase the ratio of phosphorylated to total AMPK in skeletal muscle and may have upregulated GLUT8 protein expression. The apparent increase in the expression of the GLUT8 protein in the cells could potentially enhance the movement of glucose into cells, thereby possibly improving insulin sensitivity. A study also aimed to determine whether AICAR may stimulate glucose uptake in muscle.(6) AICAR and physical activity were employed to stimulate muscle AMPK activity and glucose uptake. Results expressed the possibility that both AICAR and physical activity may increase glucose uptake in muscle. Still, AICAR may also increase glucose uptake in other tissues, thereby potentially increasing peripheral and overall insulin sensitivity. Researchers also suggested that AICAR might potentially increase the phosphorylation of extracellular signal-regulated kinase 1/2. Phosphorylation is a chemical process where a phosphate group is added to the enzymes ERK1 and ERK2. These enzymes are part of a specific signaling pathway known as the MAP kinase/ERK pathway, posited to regulate various cellular activities like division, differentiation, and response to stress. Another study observed that AICAR may potentially reduce hepatic tissues’ glucose output, lower glucose concentrations, stimulate hepatic tissues’ fatty acid oxidation, and inhibit lipolysis, thereby reducing plasma-free fatty acid availability.(7) Although AMPK phosphorylation in skeletal muscle was not reported to be increased, the researchers reported acetyl-CoA carboxylase phosphorylation to be significantly increased. This enzyme is considered to play a potential role in fatty acid metabolism. It apparently catalyzes acetyl-CoA conversion to malonyl-CoA, a crucial step in fatty acid synthesis. Thus, this inactivation could potentially lead to a decrease in fatty acid synthesis and an apparent increase in fatty acid oxidation to fuel the cells with energy. AICAR Peptide and Endurance Researchers posit that AICAR may potentially activate AMPK, glycogen phosphorylase, and fructose-1,6-bisphosphatase.(8) Some studies have suggested these potential actions may contribute to enhanced oxidative metabolism and mitochondrial biogenesis.(9) Increasing the number and function of mitochondria may benefit muscle endurance. For example, one experiment suggested that AICAR may induce metabolic genes and enhance running endurance in sedentary murine models by 44%.(10) The results suggest that peptides may target the AMPK-PPARδ pathway to enhance training adaptation or increase endurance without exercise. PPARδ, or Peroxisome Proliferator-Activated Receptor Delta, is a type of nuclear receptor that possibly plays a role in regulating genes involved in energy metabolism. It is thought that PPARδ may be involved in processes like fat-burning and mitochondrial biogenesis (the creation of new mitochondria, which are the energy-producing structures in cells). The AMPK-PPARδ pathway potentially represents a link between the sensing of energy status by AMPK and the gene regulatory functions of PPARδ. When activated, this pathway might promote adaptations in muscle cells similar to those induced by endurance training. These adaptations could include increased mitochondrial content and a shift in muscle fiber type towards more endurance-oriented fibers, potentially leading to enhanced endurance capacity.(10) Another experiment in murine models(11) also reported that the presentation of "an agonist of the AMP-activated protein kinase showed an increase in endurance compared to exercise-trained controls." Furthermore, in a murine model for Duchene muscular dystrophy, AICAR was observed by researchers to have the potential to enhance the impact of exercise and improve muscle function, probably by stimulating autophagy.(12) An infusion of AICA-riboside resulted in increment-correlated increases in forearm blood flow but did not appear to impact glucose uptake in skeletal muscle. The increase in blood flow appeared to be mediated by nitric oxide, as an inhibitor of endothelial NO synthase apparently attenuated it. These findings suggest that AICAR may exert impact in improving blood flow into muscle and acting as a NO-booster, which is also an important factor for improving performance during prolonged physical activity.(13) AICAR Peptide and Malignant Cell Lines Research indicates that AICAR may trigger apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) test models. One study proposes that this process might involve the activation of caspase-3, -8, and -9, along with the release of cytochrome C.(14) Additionally, incubating B-CLL cells with AICAR seems to lead to the phosphorylation of AMPK, hinting at AICAR's potential role in activating this protein. The research further explored whether the entry of AICAR into the cell and its conversion to AICA ribotide (ZMP) is necessary for apoptosis. It employed inhibitors like Nitrobenzylthioinosine (NBTI), 5-iodotubercidin, and adenosine. These inhibitors were suggested to potentially reduce AICAR-induced apoptosis and AMPK phosphorylation. However, inhibitors of protein kinase A and mitogen-activated protein kinases did not appear to prevent AICAR-induced apoptosis in B-CLL cells. The study also noted that AICAR did not appear to affect p53 levels or phosphorylation, suggesting a p53-independent apoptosis mechanism in B-CLL cells. A comparison was made between normal B lymphocytes, T cells, and B-CLL cells' sensitivity to AICAR-induced apoptosis. The findings indicated that normal B lymphocytes and B-CLL cells were similarly sensitive to AICAR-induced apoptosis, whereas T cells from B-CLL subjects appeared to show only minor sensitivity. Notably, AMPK phosphorylation did not seem to occur in T cells exposed to AICAR. Furthermore, upon exposure to AICAR, B-CLL cells appeared to have higher intracellular levels of ZMP compared to T cells. This observation suggests that ZMP accumulation may be crucial in activating AMPK and inducing apoptosis in these cells. AICAR peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Cieslik, K. A., Taffet, G. E., Crawford, J. R., Trial, J., Mejia Osuna, P., & Entman, M. L. (2013). AICAR-dependent AMPK activation improves scar formation in the aged heart in a murine model of reperfused myocardial infarction. Journal of molecular and cellular cardiology, 63, 26–36. https://doi.org/10.1016/j.yjmcc.2013.07.005 Mangano D. T. (1997). Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA, 277(4), 325–332. https://doi.org/10.1001/jama.277.4.325 Longnus, S. L., Wambolt, R. B., Parsons, H. L., Brownsey, R. W., & Allard, M. F. (2003). 5-Aminoimidazole-4-carboxamide 1-beta -D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. American journal of physiology. Regulatory, integrative and comparative physiology, 284(4), R936–R944. https://doi.org/10.1152/ajpregu.00319.2002 Tomita, K., Tamiya, G., Ando, S., Kitamura, N., Koizumi, H., Kato, S., Horie, Y., Kaneko, T., Azuma, T., Nagata, H., Ishii, H., & Hibi, T. (2005). AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats. Alcoholism, clinical and experimental research, 29(12 Suppl), 240S–5S. https://doi.org/10.1097/01.alc.0000191126.11479.69 de Laat, M. A., Robinson, M. A., Gruntmeir, K. J., Liu, Y., Soma, L. R., & Lacombe, V. A. (2015). AICAR administration affects glucose metabolism by upregulating the novel glucose transporter, GLUT8, in equine skeletal muscle. Veterinary journal (London, England : 1997), 205(3), 381–386. https://doi.org/10.1016/j.tvjl.2015.05.018 Cuthbertson, D. J., Babraj, J. A., Mustard, K. J., Towler, M. C., Green, K. A., Wackerhage, H., Leese, G. P., Baar, K., Thomason-Hughes, M., Sutherland, C., Hardie, D. G., & Rennie, M. J. (2007). 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes, 56(8), 2078–2084. https://doi.org/10.2337/db06-1716 Boon, H., Bosselaar, M., Praet, S. F., Blaak, E. E., Saris, W. H., Wagenmakers, A. J., McGee, S. L., Tack, C. J., Smits, P., Hargreaves, M., & van Loon, L. J. (2008). Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients. Diabetologia, 51(10), 1893–1900. https://doi.org/10.1007/s00125-008-1108-7 Višnjić D, Lalić H, Dembitz V, Tomić B, Smoljo T. AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review. Cells. 2021 May 4;10(5):1095. doi: 10.3390/cells10051095. PMID: 34064363; PMCID: PMC8147799. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011 Sep 15;25(18):1895-908. doi: 10.1101/gad.17420111. PMID: 21937710; PMCID: PMC3185962. Narkar, V. A., Downes, M., Yu, R. T., Embler, E., Wang, Y. X., Banayo, E., Mihaylova, M. M., Nelson, M. C., Zou, Y., Juguilon, H., Kang, H., Shaw, R. J., & Evans, R. M. (2008). AMPK and PPARdelta agonists are exercise mimetics. Cell, 134(3), 405–415. https://doi.org/10.1016/j.cell.2008.06.051 Goodyear, L. J. (2008). The exercise pill—too good to be true?. New England Journal of Medicine, 359(17), 1842-1844. Bueno Júnior, C. R., Pantaleão, L. C., Voltarelli, V. A., Bozi, L. H., Brum, P. C., & Zatz, M. (2012). Combined effect of AMPK/PPAR agonists and exercise training in mdx mice functional performance. PloS one, 7(9), e45699. https://doi.org/10.1371/journal.pone.0045699 Bosselaar, M., Boon, H., van Loon, L. J., van den Broek, P. H., Smits, P., & Tack, C. J. (2009). Intra-arterial AICA-riboside administration induces NO-dependent vasodilation in vivo in human skeletal muscle. American journal of physiology. Endocrinology and metabolism, 297(3), E759–E766. https://doi.org/10.1152/ajpendo.00141.2009 Campàs, C., Lopez, J. M., Santidrián, A. F., Barragán, M., Bellosillo, B., Colomer, D., & Gil, J. (2003). Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood, 101(9), 3674–3680. https://doi.org/10.1182/blood-2002-07-2339 Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Gonadorelin (GnRH) (10mg)
Gonadorelin is the synthetic version of the naturally occurring gonadotropin hormone-releasing hormone (GnRH). GnRH is considered to be a major regulator in the secretion of gonadotropins, i.e. follicle-stimulating hormone (FSH) and luteinizing hormone (LH), both of which are considered to manage and regulate the endocrine functioning and maturation of the gonads.(1) Gonadorelin is a synthetic peptide composed of ten amino acids, all joined to one another in a sequential form.(2) Gonadorelin is structurally similar to the endogenous GnRH.(3) Structurally identical to the endogenous GnRH hormones, Gonadorelin has been dubbed a GnRH agonist by researchers and exhibits some potential in regulating the levels of gonadotropins and maintaining regular reproductive functions.(2) Overview The peptide has been suggested to stimulate the synthesis and release of gonadotropins, the luteinizing hormone, and the follicle-stimulating hormone by possibly stimulating the GnRH receptors in the anterior pituitary gland cells.(4) This is mainly the reason why Gonadorelin is referred to by researchers as a "GnRH agonist," as it may possibly induce the same action as GnRH. Researchers have also suggested that excessive exposure to Gonadorelin may induce the opposite action - namely, the downregulation of GnRH receptors at the pituitary gland. This peptide hormone binds to the receptors, which, for a short period, may at first stimulate the secretion of the gonadotropins. Eventually, scientists believe the receptors become less sensitive towards this peptide, aka downregulation of the receptors, which then reversibly inhibits the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).(4) Research on this peptide and other GnRH analogs are underway, and several research hypotheses have been presented, which may be summarized thus: Gonadorelin may help researchers meter hypothalamus and pituitary gland functions; It may possibly induce ovulation; It may be a potential anticarcinogenic agent; It may reduce the likelihood of neurological deterioration. All of these hypotheses are under examination in ongoing scientific research. Chemical Makeup Molecular Formula: C55H75N17O13 Molecular Weight: 1182.31 g/mol Other Known Titles: Growth Hormone Releasing Factor, Somatocrinin, Somatoliberin Research and Clinical Studies Gonadorelin Peptide and Post-Cycle Recovery Exogenous androgens may potentially suppress the function of the hypothalamic-pituitary-gonadal (HPG) axis, which is considered to form between the structures of the hypothalamus, the pituitary gland, and the gonads. For example, exogenous androgens are suggested to mediate negative feedback to the pituitary gland, thereby suppressing the release of LH and FSH. Once the exposure to exogenous androgens has ceased, HPG may slowly recover, but Gonadorelin may offer a potential mechanism to speed up the process. For example, one study reported exogenous androgen exposure, which led to LH and FSH being suppressed to less than 0.5 IU/L while endogenous testosterone produced by testicular cells was down to 4.5 nmol/L. Short exposure to Gonadorelin resulted in apparent increases up to 7.9 IU/L for LH, up to 2.4 IU/L for FSH, and 13.3 nmol/L for endogenous testosterone. Moreover, these improvements were apparently sustained for over 12 months without further exposition to the peptide.(5) Gonadorelin Peptide and Testicular Function Studies have investigated the potential of intermittent Gonadorlein exposure on the HPG axis, which may mimic the natural synthesis of GnRH and its action on the pituitary cells. In particular, this scenario was studied in models of hypothalamic dysfunction, where the production of native GnRH appeared to have been disturbed. Researchers have shared that Gonadorelin may effectively " kick-start” the HPG axis in such scenarios, which involves sequential stimulation of the pituitary gland cells to synthesize LH and FSH, and then the testicular cells to produce androgens. They comment that intermittent exposure to the peptide for 5 to 6 months may ultimately result in successful spermatogenesis. This process appears to be highly dependent on the endogenous production of testosterone by testicular cells.(6)(7) Further research has also suggested that Gonadorelin may help facilitate the descent of the testes, which is considered a part of the development of the HPG axis. Researchers posit that the peptide may have roughly 40% success rate at inducing such processes, related to the maturation of the HPG axis and testicular structures in particular.(8) Gonadorelin Peptide and Cancer Cells Research in cancer cell proliferation in both clinical and animal studies suggests that excessive exposure of breast cells to mitogens, namely estrogen and progesterone, may increase the risk of their transformation into cancer cells. Potentially blocking the action of these mitogens, thereby reducing the exposure of the healthy cells to them, may reduce the risk of cancer development.(9) Researchers suggest that GnRH agonists such as Gonadorelin may exhibit some potential in mitigating the action of mitogens in healthy cells. Studies(10) examining research models of high testosterone, a marker for hyperandrogenemia (a condition characterized by excessive androgen synthesis), are at higher risk of developing breast cancer. The source of androgen, and thereby the potential source of breast cancer, may possibly be counteracted with GnRH analogs, as researchers are hypothesizing that the peptide may induce a reduction in the substrate for estrogen synthesis but may not necessarily inhibit the synthesis of estrogen completely. Researchers have also explored the potential of Gonadorelin in experimental studies intended to inhibit the production of luteinizing hormones. The researchers suggested that due to the potential for downregulating GnRH receptors, the peptide may lead to a decline in the production of testosterone and dihydrotestosterone. The development of carcinogenic cells from prostate cells may depend on these testosterone levels, which the exposure to GnRH analogs such as Gonadorelin might inhibit.(11) Gonadorelin Peptide and Spermatogenesis In a clinical trial,(12) seven male test subjects were presented with a GnRH analog similar to Gonadorelin every day for up to 16 weeks and a compound of testosterone enanthate bimonthly (a form of TRT). Basal serum follicle-stimulating hormone, luteinizing hormones, and testosterone levels were monitored throughout the study period. Between 14 to 16 weeks, it was noted by the researchers that the average sperm count in the test subjects had reportedly reduced by an average of 93%, also causing azoospermia in three of the subjects, which is characterized by a complete absence of sperms in the ejaculate. Subsequently, once the study was completed, the average sperm count returned to normal, indicating that the possible action of the peptide hormone may be reversible and act as a temporary contraceptive (when combined with TRT). Gonadorelin Peptide and Neuroprotection Research(13) has suggested that luteinizing hormones may have some impact on the brain, primarily the hippocampus, which is the memory center of the brain, and in some scenarios, may possibly induce some dysfunction. These researchers posited that one way of mitigating neurological dysfunction might be to block the production and release of luteinizing hormones, which may potentially be achieved through the introduction of GnRH analogs such as Gonadorelin. Testosterone has also been studied by scientists for its potential to preserve memory function and may be beneficial to brain function. Hence, inhibiting the entire gonadal axis may not be fully beneficial. This is why GnRH, which researchers suggest only induces selective inhibitory action on luteinizing hormones, may exhibit potential in future research studies.(13) Gonadorelin Peptide and Diagnostics In this clinical study,(14) the synthetically developed peptide Gonadorelin was presented in 11 female test subjects during the middle of the follicular phase of the menstrual cycle. All subjects exhibited an apparent increase in the basal levels of gonadotropins following peptide presence. In addition, 10 test subjects with amenorrhea were presented with the peptide. Amenorrhea is characterized by a lack of menstruation. After the study, researchers reported that basal levels of gonadotropins, particularly the luteinizing hormone levels, appeared to increase in the short term but remained steady in the long term. This study suggested that Gonadorelin's potential pituitary secretion of luteinizing hormones and follicle-stimulating hormones may not depend on the basal levels of these hormones. However, it may depend on the functioning of the hypothalamic and pituitary axis. Gonadorelin peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Marques P, Skorupskaite K, George JT, et al. Physiology of GNRH and Gonadotropin Secretion. [Updated 2018 Jun 19]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK279070/ National Center for Biotechnology Information. PubChem Compound Summary for CID 638793, Gonadorelin. Philip GA Thomas, Alain Fontbonne, Drugs and reproduction. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/gonadorelin-acetate van Breda, E., Keizer, H. A., Kuipers, H., & Wolffenbuttel, B. H. (2003). Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. International journal of sports medicine, 24(3), 195–196. https://doi.org/10.1055/s-2003-39089 Blumenfeld, Z., Makler, A., Frisch, L., & Brandes, J. M. (1988). Induction of spermatogenesis and fertility in hypogonadotropic azoospermic men by intravenous pulsatile gonadotropin-releasing hormone (GnRH). Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2(2), 151–164. https://doi.org/10.3109/09513598809023623 Zhang, L., Cai, K., Wang, Y., Ji, W., Cheng, Z., Chen, G., & Liao, Z. (2019). The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men. American journal of men's health, 13(1), 1557988318818280. https://doi.org/10.1177/1557988318818280 Muzzi, G., Bartolotta, E., Cherubini, V., & Lomiento, D. (1990). Effetti del trattamento con LH-RH sintetico spray nasale nel criptorchidismo [Effects of the treatment using synthetic LH-RH nasal spray in cryptorchism]. La Pediatria medica e chirurgica : Medical and surgical pediatrics, 12(1), 53–55. Lepor, Herbert. “Comparison of single-agent androgen suppression for advanced prostate cancer.” Reviews in urology vol. 7 Suppl 5,Suppl 5 (2005): S3-S12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1477619/ Spicer DV, Pike MC. Sex steroids and breast cancer prevention. J Natl Cancer Inst Monogr. 1994;(16):139-47. https://pubmed.ncbi.nlm.nih.gov/7999456/ Secreto G, Sieri S, Agnoli C, Grioni S, Muti P, Zumoff B, Sant M, Meneghini E, Krogh V. A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women. Breast Cancer Res Treat. 2016 Aug;158(3):553-61. https://pubmed.ncbi.nlm.nih.gov/27393623/ Zerbib M. Analogues de la GnRH dans le traitement du cancer de la prostate [GnRH analogs and prostate cancer treatment]. Ann Urol (Paris). 2005 Oct;39 Suppl 3:S66-72. French. doi: 10.1016/s0003-4401(05)80011-7. https://pubmed.ncbi.nlm.nih.gov/16302714/ Bhasin S, Yuan QX, Steiner BS, Swerdloff RS. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and androgen. J Clin Endocrinol Metab. 1987 Sep;65(3):568-74. https://pubmed.ncbi.nlm.nih.gov/3114307/ R.L Bowen, et al, Not All Androgen Deprivation Therapies Are Created Equal: Leuprolide and the Decreased Risk of Developing Alzheimer's Disease, J. Clin. Oncol., vol 34, no. 23, p.2800, Aug 2016. https://ascopubs.org/doi/full/10.1200/JCO.2015.66.3997 Vesper B, Rohde W, Groot-Wassink T. Ein Beitrag zur klinischen Anwendung von Gonadorelin als Diagnostikum im Einfach- und Doppelbelastungstest [Clinical use of Gonadorelin as a diagnostic agent in one- and two-step tests]. Zentralbl Gynakol. 1986;108(23):1442-52. https://pubmed.ncbi.nlm.nih.gov/3103350/ Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Tesamorelin (5mg / 10mg)
Tesamorelin is a synthetic polypeptide composed of 44 amino acids analogous to growth hormone-releasing hormone. The N-terminus of the compound has been modified compared to growth hormone-releasing hormone, the modification of which researchers suggest may lead to improved stability.(1) Tesamorelin has been studied for its potential mechanism of action, posited to be similar to growth hormone-releasing hormones (GHRH) receptors located at the anterior pituitary gland, possibly leading to increased production and secretion of growth hormones. Growth hormones may act on several cells, including hepatocytes, stimulating the systemic synthesis of insulin-like growth factor-1 (IGF-1). In addition, growth hormone may also stimulate IGF-1 production locally, inside various tissues.(1) Overview IGF-1 has been posited to be the main anabolic mediator of growth hormone, potentially working to stimulate growth and inhibit programmed cell death.(1) On the other hand, growth hormone itself is suggested to be lipolytic, inducing fat breakdown at specific adipose depots, such as abdominal and visceral fat depositions. Tesamorelin appears to stimulate the release of growth hormone, and consequently IGF-1, by potentially interacting with the GHRH receptors in the anterior pituitary gland cells. When Tesamorelin interacts with the GHRH receptor, it is hypothesized that this interaction might alter the receptor's structure, potentially initiating communication pathways within the cell. It is also theorized that Tesamorelin might enhance the production of cyclic adenosine monophosphate (cAMP) in certain cells. This process may occur through the stimulation of adenylate cyclase, an enzyme that converts adenosine triphosphate (ATP) into cAMP. Increased cAMP levels may lead to the activation of protein kinase A (PKA), an enzyme deemed critical for transmitting signals within cells. Activated PKA may phosphorylate various target proteins, triggering a cascade of cellular responses. The conjectural stimulation of the GHRH receptor by Tesamorelin and the cAMP-PKA signaling pathway might promote the secretion and distribution of growth hormone (hGH) from somatotroph cells in the pituitary gland. Research indicates that this peptide may lead to an estimated 69% increase in overall growth hormone levels, measured by the area under the curve (AUC), and a reported 55% increase in the mean pulse area of the growth hormone. However, it does not seem to influence the frequency or peak levels of growth hormone pulses. Additionally, IGF-1 levels apparently surged by 122%.(3) The N-terminus and C-terminus of the GHRH molecule are altered in Tesamorelin, potentially lending stability to the peptide and possibly increasing the compound's resistance to enzyme deactivation compared to natural GHRH.(4) Focusing on the specific alterations, the C-terminus of Tesamorelin is modified by the addition of a trans-3-hexenoic acid group. This particular change, often referred to as an omega-amino acid modification, is believed to potentially reinforce the peptide's defense against enzymatic breakdown. On the other end, the N-terminus is modified by the attachment of an acetyl group, represented by the chemical notation CH₃CO-. This acetylation might enhance not only the molecule's stability but also its biological activity. As a result of these specific modifications, Tesamorelin is designated chemically as N-(trans-3-hexenoyl)-[Tyr1]hGRF(1–44)NH2 acetate, highlighting the specific alterations made to the peptide. Chemical Makeup Molecular Formula: C221H366N72O67S Molecular Weight: 5136 g/mol Other Known Titles: (3E)-hex-3-enoylsomatoliberin Research and Clinical Studies Tesamorelin Peptide and Lipodystrophy Lipodystrophy models refer to abnormal or pathological fat distribution and metabolism. The primary feature of lipodystrophy is the irregular distribution of fat into depots, leading to loss of fat (lipoatrophy) from specefic areas, and accumulation of excess fat (lipohypertrophy) in other regions. This abnormal fat distribution is often associated with serious negative metabolic changes, including insulin resistance, elevated cholesterol and triglyceride levels. Test models exhibiting lipodystrophy report low levels of GH and IGF-1. Researchers studying Tesamorelin's action and potential impact, suggest that the peptide may positively influence lipid metabolism, especially in lipodystrophy models. For example, two phase III studies(6) were conducted with 806 test subjects over 26 weeks, followed by another 26-week extension. Each of the 806 test subjects had immunodeficiencies and lipodystrophy. The subjects were divided into two groups; one group with 543 subjects was presented with Tesamorelin, and the remaining 263 subjects were presented with a placebo for 26 weeks. After this duration, the Tesamorelin subjects were again randomly divided into 2 groups, in which one group continued Tesamorelin influence, and the other half was presented with a placebo for another 26 weeks. At week 26, the researchers observed a significant decrease in visceral adipose tissue level amongst the Tesamorelin subjects, at least 15.4%. Additionally, the levels of triglyceride and cholesterol were reported significantly decreased compared to the placebo group. Tesamorelin Peptide and Immunodeficient Fat Fractions Researchers posit that serious immunodeficiencies may induce non-alcoholic fatty liver disease (NAFLD), which in clinical cases is reported in nearly 40% of HIV-positive test models.(7) In this study,(5) 61 test subjects with HIV and a high hepatic fat fraction (HFF) were selected as test models. These subjects were influenced with Tesamorelin or a placebo for 12 months. The rate of HFF was monitored at the end of the study. After 12 months, it was reported by the researchers that 35% of subjects presented with Tesamorelin exhibited an apparent reduction in HFF rate by less than 5% vs. only 4% of subjects receiving placebo exhibited any HFF reduction. There was no reported alteration in the glucose levels. Tesamorelin Peptide and Cognition In this clinical study,(8) immunodeficient models with mild cognitive impairment were observed. The main intent of this study was to determine Tesamorelin's potential effect on neurological functioning. 100 subjects, aged more than 40 years, participated in this trial and underwent Tesamorelin presentation daily for 6 months, followed by all absence of Tesamorelin influence for the next 6 months. Then Tesamorelin was re-introduced once a day for another 6 months. The primary outcome of this study was reported in changes in neurocognitive performance measured by the Global Deficit Score (GDS) after 6 and 12 months. This study is underway, and the final results have not been published. Tesamorelin Peptide and Insulin The main aim of this study(9) was to determine any potential Tesamorelin might exhibit in altering insulin sensitivity. In this clinical trial setting, 53 test subjects with Type II diabetes were observed in this 12-week randomized trial. The subjects were divided into three groups, each receiving a lower or higher concentration of Tesamorelin or a placebo. Following the study period of 12 weeks, the concentration of fasting glucose, glycosylated hemoglobin, and diabetes control was measured. There was no reported significant reduction in either of these parameters. The results of all three groups appeared to be indifferent. Tesamorelin Peptide and Muscle Tissue In a research investigation, the possible impacts of Tesamorelin on the structural quality of muscle tissues were evaluated using computed tomography (CT) scans.(10) Computed tomography (CT) is an imaging tool that combines X-rays and computer technology to produce detailed pictures of internal structures. The findings from this study tentatively suggested a potential association between Tesamorelin and improvements in the density and overall volume of muscle tissues. It was observed that specific muscle groups, particularly the rectus abdominis, psoas major, and paraspinal muscles, exhibited more noticeable variations. These variations consisted of either increased muscle density and volume or decreased fat within the muscle tissue. From a statistical perspective, the alterations in muscle density and size or the reduction in fat content in these specific muscles were significantly different when compared to results from a control group receiving a placebo. Tesamorelin Peptide and Visceral Fat Visceral obesity involves the accumulation of excess fat around and within internal organs, a condition often observed in models of lipodystrophy—a disorder characterized by abnormal distribution of fat cells. This form of excessive fat accumulation is potentially linked to several metabolic issues. These issues include insulin resistance, a diminished ability to respond to insulin leading to elevated blood glucose levels. Additionally, visceral obesity is associated with the development of atherosclerosis, a condition where plaque builds up in the arteries, elevated levels of low-density lipoprotein (LDL) cholesterol, and hyperuricemia, an excess of uric acid. The significance of these models extends beyond aesthetic concerns, indicating that lipodystrophy may precipitate profound metabolic disturbances. In addressing these challenges, Tesamorelin, a synthetic form of the growth-hormone-releasing factor, has been proposed as a possibly positive avenue for further development. Research into Tesamorelin has suggested it may lead to a reduction of up to 25% in visceral fat among lipodystrophy models.(11) Tesamorelin peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tesamorelin. [Updated 2018 Oct 20]. https://www.ncbi.nlm.nih.gov/books/NBK548730/ Spooner, L. M., & Olin, J. L. (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. The Annals of pharmacotherapy, 46(2), 240–247. https://doi.org/10.1345/aph.1Q629 Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011 Jan;96(1):150-8. doi: 10.1210/jc.2010-1587. Epub 2010 Oct 13. PMID: 20943777; PMCID: PMC3038486. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038486/ Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):49-58. doi: 10.1111/j.1742-7843.2007.00008.x. PMID: 17214611. https://pubmed.ncbi.nlm.nih.gov/17214611/ Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Aepfelbacher, J., Buckless, C., Tsao, A., Kellogg, A., Branch, K., Lee, H., Liu, C. Y., Corey, K. E., Chung, R. T., Torriani, M., Kleiner, D. E., Hadigan, C. M., & Grinspoon, S. K. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The lancet. HIV, 6(12), e821–e830. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981288/ Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/ Tesamorelin Effects on Liver Fat and Histology in HIV. https://clinicaltrials.gov/ct2/show/NCT02196831 Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons. https://clinicaltrials.gov/ct2/show/record/NCT02572323 Clemmons, D. R., Miller, S., & Mamputu, J. C. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PloS one, 12(6), e0179538. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472315/ Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. doi: 10.14283/jfa.2018.45. PMID: 31237318; PMCID: PMC6766405. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766405/ Sivakumar T, Mechanic O, Fehmie DA, Paul B. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. HIV Med. 2011 Sep;12(8):453-62. doi: 10.1111/j.1468-1293.2010.00906.x. Epub 2011 Jan 25. PMID: 21265979. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
KPV (4mg)
Alpha melanocyte-stimulating hormone (a-MSH) is also classified as a melanotropin. a-MSH is an endogenous peptide hormone, composed of 13 amino acids, and considered to play a role in metabolic function, as well as other biological processes. Scientists isolated a fragment of this protein hormone and identified its potential biological action, naming it KPV peptide. KPV comprises three amino acids: Lysine, Proline, and Valine.(1) This peptide is a C-terminal fragment of the a-MSH protein hormone, which is considered the primary amino acid sequence in the hormone responsible for its properties.(2) A study(2) was published in 1989 explaining how the tripeptide was isolated and its biological potential determined. Upon discovering that the COOH terminal peptide in the a-MSH hormone is the primary amino acid messenger sequence, scientists conducted preliminary research to determine if KPV might prevent an excessive increase in vasopermeability and excessive swelling of blood vessels. As a part of the study, scientists isolated the KPV peptide and presented it to experimental mice to determine its potential to mitigate swelling in their ears. After the completion of the study, the researchers reported that the isolated fragment appeared to have inhibited the swelling. KPV's potential anti-inflammatory action may be induced by inactivating the inflammatory pathways.(3) It may also possibly inhibit the synthesis and release of the pro-inflammatory cytokine cells in intestinal and immune cells. Chemical Makeup Molecular Formula: C16H30N4O4 Molecular Weight: 342.43 g/mol Other Known Titles: MSH (11-13), ACTH(11-13), alpha-MSH(11-13) Research and Clinical Studies KPV Peptide and Intestinal Protection A study(4) was conducted on murine models to determine the peptide's potential on intestinal inflammation. The experiment was conducted on mice induced with bowel dysfunction. These mice were divided into two groups: one group was given the peptide, and the other was given the placebo. After the study, researchers reported that the peptide mice exhibited reduced inflammatory cells and anti-enzymatic symptoms. Another study(4) was conducted on a murine model of inflamed intestines, which involved the exposure of a chemical-induced compound of KPV and a chemical called hyaluronic acid. This chemical-induced KPV compound was given to the mice, with the added hyaluronic acid supplementation, intended to aid targeted delivery of the peptide to specific locations in the intestine. The results observed mitigated swelling in the intestine. KPV Peptide and Intestinal Cells One study(5) was conducted on a cell culture of inflamed intestinal cells. The main purpose of this study was to determine the peptide’s potential against inflammation. Inflamed intestinal cells were isolated and exposed to either the KPV peptide or a placebo. Upon exposure to the peptide, these cells were examined, and results indicated that even nanomolar concentrations of the peptide appeared to have led to anti-inflammatory results. The researchers suggested that the KPV peptide appeared to mainly act via PepT1 expression in these intestinal cells, suggesting that PepT1 may play a role in transporting the peptide to the site of inflammation. Another study delved into the potential of KPV in addressing ulcerative inflammation of the colonic mucosa cells.(6) The researchers hypothesized that KPV might mitigate inflammatory responses within colonic cells, by accelerating mucosal healing and alleviating inflammation of the colonic mucosa. The action mechanism was suggested to involve the targeted delivery of KPV to inflamed colonic tissues, where it may exert anti-inflammatory potential. The researchers found that KPV may have exhibited a capacity to protect mucosal surfaces and downregulate TNF-α, a key marker of inflammation. Further trials in two murine models of intestinal inflammation suggest that KPV may have led to significant improvements, including earlier recovery, significant regain of body weight, and a reduction in inflammatory infiltrates, in the colonic tissue.(7) These outcomes were further supported by a notable decrease in myeloperoxidase (MPO) activity, indicating reduced neutrophil accumulation and inflammation in colonic tissue following KPV exposure. Moreover, the study explored whether KPV's anti-inflammatory actions may have been linked to the melanocortin-1 receptor (MC1R), suggesting that the action of KPV might at least be partially independent of MC1R signaling. One 1984 study aimed to evaluate the potential antipyretic action of the peptide,(8) wherein rabbits were given KPV peptide to examine its potential action on the nervous system. Following the study, researchers suggested that the peptide exhibited antipyretic potential, reducing the rabbits’ body temperature to optimal levels. KPV Peptide and Inflammation Studies A comparative study analysis(9) was conducted to examine the potential of a-MSH and KPV on the swelling (inflammation) of organs. An experiment was conducted on the mice with swollen ears due to skin rashes and dermatitis. The mice were divided into two groups - one was given an irritant (to induce ear swelling) and then exposed to the peptide, and the other with the irritant and the a-MSH molecule. After 24 hours, both groups exhibited apparently equal improvement in reducing ear swelling. After 2 weeks, researchers ceased exposure to both compounds, and only the irritant was given, with the results observing that the a-MSH mice appeared to continue to show reduced swelling compared to the other group. KPV Peptide and Wound Healing Wound healing is a complex biological process comprised of three general phases: inflammation, proliferation, and remodeling of the skin, tissue, or cells. This process is characterized by different types of cells and concentrations of cytokines in the wounded area. Though every wound and associated cells affected by the wound may differ, most cells possess a melanocortin 1 receptor (MC1R) receptor. This receptor is where the a-MSH hormone binds, and researchers suggest that a-MSH hormone analogs, such as KPV peptide, may also bind to these receptors.(10) Another study explored the potential of KPV in enhancing corneal epithelial wound healing with a particular focus on the possible involvement of nitric oxide (NO) in these actions. Following mechanical abrasion to damage the corneal epithelium, the tissue was exposed to variable concentrations of the KPV peptide. The progress of epithelial wound healing was meticulously tracked and analyzed through computerized software, comparing the mean area of the epithelial defect among experimental groups at multiple time intervals. The findings suggested a potential acceleration in the healing process in corneal tissues compared to placebo. Specifically, within 60 hours, all corneas exposed to KPV appeared to have complete re-epithelialization, a stark contrast to the placebo group, where none of the corneas appeared to have achieved full healing. This accelerated healing effect was apparently hindered by pre-treatment with the nitric oxide synthase inhibitor, Nω-nitro-l-arginine methyl ester (l-NAME), suggesting that the facilitating impact of KPV on corneal epithelial wound healing might be linked to NO activity within the corneal tissue. Further in vitro experiments with corneal epithelial cells (RCE) exposed to different concentrations of KPV reportedly exhibited a stimulation of cell viability at 1 and 10 μM concentrations. These results suggest that KPV may not only accelerate corneal epithelial wound healing but also might stimulate cell viability, hinting at a broader reparative role that may involve NO dynamics.(11) KPV Peptide and Scar Formation A study(12) was conducted to further understand the potential of KPV peptide in scar recovery. The experiment was conducted in murine models, half of the group of young mice were exposed to KPV, and the other served as a control group. Half an hour after exposure, these mice underwent two surgical 6.5 mm wide incisions in their dorsal skin under anesthesia. The wound healing and scar formation were analyzed on days 3, 7, 40, and 60. On days 3 and 7, researchers observed that the peptide mice appeared to show improved healing on the skin, possibly due to reduced levels of inflammatory cells such as leukocytes and mast cells. On days 40 and 60, it was observed that the peptide mice exhibited a lesser scar area than the control group. KPV peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References: Dalmasso, G., Charrier-Hisamuddin, L., Nguyen, H. T., Yan, Y., Sitaraman, S., & Merlin, D. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1), 166–178. https://doi.org/10.1053/j.gastro.2007.10.026 Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989 Sep;3(11):2282-4. https://pubmed.ncbi.nlm.nih.gov/2550304/ Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008 Aug;29(5):581-602. doi: 10.1210/er.2007-0027. Epub 2008 Jul 8. https://pubmed.ncbi.nlm.nih.gov/18612139/ Klaus Kannengiesser, MD, Christian Maaser, MD, Jan Heidemann, MD, Andreas Luegering, MD, Matthias Ross, MD, Thomas Brzoska, PhD, Markus Bohm, MD, Thomas A. Luger, MD, Wolfram Domschke, MD, Torsten Kucharzik, MD, Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease, Inflammatory Bowel Diseases, Volume 14, Issue 3, 1 March 2008, Pages 324–331, https://doi.org/10.1002/ibd.20334 Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008 Jan;134(1):166-78. https://pubmed.ncbi.nlm.nih.gov/18061177/ Xiao, B., Xu, Z., Viennois, E., Zhang, Y., Zhang, Z., Zhang, M., Han, M. K., Kang, Y., & Merlin, D. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular therapy : the journal of the American Society of Gene Therapy, 25(7), 1628–1640. https://doi.org/10.1016/j.ymthe.2016.11.020 Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008 Mar;14(3):324-31. doi: 10.1002/ibd.20334. PMID: 18092346. D.B. Richards, J.M. Lipton, Effect of α-MSH 11–13 (lysine-proline-valine) on fever in the rabbit, Peptides, Volume 5, Issue 4, 1984, Pages 815-817, ISSN 0196-9781, https://doi.org/10.1016/0196-9781(84)90027-5 Luger, T. A., & Brzoska, T. (2007). alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the rheumatic diseases, 66 Suppl 3(Suppl 3), iii52–iii55. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095288/#!po=3.33333 Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008 Aug;29(5):581-602. https://pubmed.ncbi.nlm.nih.gov/18612139/ Bonfiglio V, Camillieri G, Avitabile T, Leggio GM, Drago F. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res. 2006 Dec;83(6):1366-72. doi: 10.1016/j.exer.2006.07.014. Epub 2006 Sep 11. PMID: 16965771. de Souza KS, Cantaruti TA, Azevedo GM Jr, Galdino DA, Rodrigues CM, Costa RA, Vaz NM, Carvalho CR. Improved cutaneous wound healing after intraperitoneal injection of alpha-melanocyte-stimulating hormone. Exp Dermatol. 2015 Mar;24(3):198-203. https://pubmed.ncbi.nlm.nih.gov/25431356/ Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Mod GRF 1-29 & GHRP-2 Blend (10mg)
GHRP-2 and Modified GRF 1-29 peptides are synthetic peptides developed with the intention to aid in synthesis, secretion, and regulation of growth hormone synthesis. These peptides appear to exert synergistic action when taken together as a blend. GHRP-2 is a synthetic peptide that apparently activates the receptors for ghrelin.(1) Ghrelin is a naturally occurring peptide containing 28 amino acids that is considered by scientists to regulate growth hormones, and increase appetite.(2) This is why it is also referred to as ‘the hunger hormone.’ GHRP-2 appears to activate the ghrelin receptors in the pituitary gland, which are also called growth hormone secretagogue receptors, and thus may potentially stimulate growth hormone release. Thus, GHRP-2 has been characterized by researchers as a growth hormone secretagogue (GHS). Modified GRF 1-29 (or Mod GRF 1-29) is a man-made peptide analog to the naturally occurring growth hormone-releasing hormones (GHRH). It is made of the first 29 amino acids of the native hormone, which appears sufficient for activating the GHRH receptors in the somatotroph cells in the anterior pituitary gland and triggering growth hormone release. Structurally similar to GRF 1-29, the peptide contains a chain of 29 amino acids and is slightly modified for proposed durability by substituting four of the amino acids in the original amino acid-chain.(3) These modifications appear to enhance the pharmacokinetics of the peptide. GHRP-2 and Mod GRF 1-29 have been studied for their individual potential to stimulate the somatotroph cells in the pituitary gland, possibly triggering the secretion of growth hormone.(4) Chemical Makeup (3)(5) Molecular formula: Modified GRF 1-29: C152H252N44O42 GHRP-2: C45H55N9O6 Molecular weight: Modified GRF 1-29: 3367.9 g/mol GHRP-2: 817.9 g/mol Other known titles: Modified GRF 1-29: Mod GRF 1-29, CJC-1295 without DAC GHRP-2: Pralmorelin, Growth hormone-releasing peptide-2 Research and Clinical Studies Modified GRF 1-29 & GHRP-2 Peptide Blend and Tolerability Research studies in animal models(5) have conducted to understand the various potential actions of GHSs such as GHRP-2. According to researchers, the presentation of the peptides in both guinea pigs and rabbits did not result in any serious or profound action on the tested experimental models. The only reported change was seen was an increase in the motility rate of the isolated ileum of rabbits and increased muscle contractions in the isolated ileum of the guinea pigs. No other impacts were observed on the kidneys, respiratory, gastric, and blood systems. As per Furuta S et al., these results suggest that the peptide “has no serious general pharmacological effects at dose levels showing GH-releasing activity in the experimental animals. Therefore, it is concluded that the peptide [may be useful in] diagnosing serious GH deficiency and treating short stature.” (5) Modified GRF 1-29 & GHRP-2 Peptide Blend and Appetite Due to its potential to activate the ghrelin receptors not just in the pituitary gland but also in other areas, GHRP-2 is considered the likely compound for inducing hunger and appetite increase in this peptide blend. A clinical trial(6) was carried out in which seven test subjects were observed. The subjects in the trial were divided into two groups – one experimental peptide group and a placebo (saline) group receiving each of the compounds for approximately 5 hours. After peptide presentation, all subjects were taken to buffet-style meals to measure their food intake. The peptide group were reported to have consumed approximately 35% more food measured in kilocalories than the saline group, with each subject exhibiting increased appetite when measured against their body weight. Moreover, the concentration of growth hormone also appeared to increase significantly in the peptide test subjects. These results indicate a possibility that one of the additional actions of the peptide blend may be increased food intake and appetite, particularly due to the presence of GHRP-2. General Research in Growth Hormone Secretagogues (GSHs), Growth Hormone Releasing Peptides (GHRPs) A literature review(7) aimed to evaluate the potential impacts of growth hormone secretagogues (GSHs) such as GHRP-2. As part of some of the studies included in the review, subjects were monitored for physiological changes after being presented with the peptide. The results suggested that these peptides appeared to yield an increased growth rate in younger subjects, with increased appetite, and increased lean mass in mature subjects. In obese test subjects, these peptides appeared to stimulate a reduction in bone turnover, increased lean mass, and improved sleep cycle. The researchers stated that these peptides appear to “increase lean body mass, reduce fat mass, increase exercise tolerance and maximum oxygen uptake, enhance muscle strength, and improve linear growth.”(7) Modified GRF 1-29 & GHRP-2 Peptide Blend and Growth Hormone Deficiency Since 2000, several clinical studies have been conducted on test models of growth hormone deficiency. Models presented with the GHRP-2 peptide stimulating growth hormone release indicated that this peptide might produce action in two ways, including (i) possibly stimulating the pituitary gland to release growth hormones and (ii) acting on the arcuate nucleus of the hypothalamus. While GHRP-2 appears to yield high concentrations of growth hormone, it remains to be seen how its action is exerted. In addition, these studies suggested that these peptides may impact food intake and sleep cycle via receptor-specific agonist actions.(8) In another GHRP-2 study focusing on young test subjects, six growth hormone-deficient subjects facing growth failure were presented with different concentrations of the peptide for eight months.(9) All subjects were monitored for any significant rise in growth hormone levels and toxicity levels during this period. Throughout the study, there appeared to be a steep rise in the levels of growth hormones in all subjects for the duration of the study and a little time after. As per V Mericq et al., the study suggested that the peptide was “well tolerated and [may] stimulate GH secretion.” Modified GRF 1-29 & GHRP-2 Peptide Blend and Hormones In one clinical study,(10) the primary objective was to understand the impact of GHRP-2 presentation on growth hormones, cortisol, prolactin, and adrenocorticotropic hormone (ACTH) levels in male test subjects. All subjects were divided into two groups based on their age – the first group had six mature subjects aged between 22 and 27 years, and the second group had 6 mature subjects aged between 66 and 73 years. Both groups were presented with GHRP-2. While the growth hormone levels increased in both groups, the younger group was observed to have a significant increase compared to the elderly subjects. It also appeared to stimulate increased levels of ACTH and cortisol hormones and a mild increase in prolactin levels. The results supported the hypothesis that the peptide may have profound hormonal secretion capabilities in both mature and young male test subjects. Modified GRF 1-29 & GHRP-2 Peptide Blend and the GHRH receptors While GHRP-2 appears to function by binding to the GHS-R1a receptor, often referred to as the growth hormone secretagogue receptor type 1a, Mod GRF 1-29 appears to promote growth hormone release by potentially engaging with the GHRH receptors located on the somatrophs of the anterior pituitary gland. Upon binding to these receptors, Mod 1-29 appears to potentially trigger a series of intracellular signals. A notable pathway that gets activated is the adenylyl cyclase pathway, which might lead to the transformation of ATP (adenosine triphosphate) into cAMP (cyclic adenosine monophosphate). The subsequent increase in cAMP levels seems to stimulate protein kinase A (PKA), possibly resulting in the phosphorylation of specific proteins, such as the voltage-dependent calcium channels on the cellular membrane. The opening of these channels might allow calcium ions to flow into the somatotropic cells. This surge in intracellular calcium seems to encourage the secretory vesicles within these cells to discharge growth hormone into the bloodstream. Researchers have suggested that Mod GRF 1-29, through these cellular processes, may aid in the release and production of growth hormone upon interaction with GHRH receptors. Modified GRF 1-29 & GHRP-2 Peptide Blend and the Insulin-like Growth Factor-1 (IGF-1) A comprehensive review of the literature suggests that both the GHRH-mimetics like Mod GRF-1 and the GHS GHRP-2 may upregulate growth hormone levels and consecutively its main anabolic mediator IGF-1. The researchers comment that the unmodified version of Mod GRF-1 may apparently boost mean growth hormone levels by 82% in research conditions, as indicated by area under the curve (AUC) measurements. The growth hormone concentrations appeared elevated for about two hours after the intervention.(11) Other trials have also suggested a potential 64% increase in mean growth hormone levels as measured by AUC, and the increase appeared greater in studies conducted in the evening, compared to those conducted in the morning. This apparent increase in growth hormone levels has also been suggested to occur in modified versions of GRF 1-29 which closely resemble Mod GRF-1 and have been posited to reach 70-107% increase in growth hormone levels measured by AUC. This potentially translates to a significant increase in IGF-1 levels of 27-28%.(11) Another trial covered in the aforementioned review also suggested that the combination of unmodified Mod GRF 1-29 and GHSs like GHRP-2 might result in whopping 65% increase in IGF-1 levels.(11) Modified GRF 1-29 & GHRP-2 Peptide Blend and Synergistic Potential As mentioned, both Mod GRF 1-29 and GHRP-2 appear to stimulate the release of growth hormone. The available research suggests that GHRP-2 may lead to a 47-fold increase in pulsatile growth hormone secretion. Unfortunately, there is a lack of experiments revealing how much exactly Mod GRF 1-29 may upregulate growth hormone synthesis. Yet trials on another GHRH-mimetic, more specifically the non-truncated and unmodified version of Mod GRF 1-29 which has shorter half life, appear to lead to a 20-fold increase in pulsatile growth hormone secretion. It has been hypothesized that the combination of such GHRH-mimetics and the secretagogue GHRP-2 may potentially exhibit synergistic potential in regards to their apparent stimulation of growth hormone secretion. Notably, when combining GHRH and GHRP-2, the blend was observed to induce a 54-fold increase in pulsatile GH secretion compared to controls, suggesting a synergistic potential.(11) Mod GRF 1-29 & GHRP-2 blend is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering. References Garcia JM, Merriam GR, Kargi AY. Growth Hormone in Aging. [Updated 2019 Oct 7]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com https://www.ncbi.nlm.nih.gov/books/NBK279163/ Phung LT, Sasaki A, Lee HG, Vega RA, Matsunaga N, Hidaka S, Kuwayama H, Hidari H. Effects of the administration of growth hormone-releasing peptide-2 (GHRP-2) orally by gavage and in feed on growth hormone release in swine. Domest Anim Endocrinol. 2001 Jan;20(1):9-19. https://pubmed.ncbi.nlm.nih.gov/11164330/ National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 91976842, CJC1295 Without DAC. https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC. Roh SG, He ML, Matsunaga N, Hidaka S, Hidari H. Mechanisms of action of growth hormone-releasing peptide-2 in bovine pituitary cells. J Anim Sci. 1997 Oct;75(10):2744-8. doi: 10.2527/1997.75102744x. PMID: 9331879. https://pubmed.ncbi.nlm.nih.gov/9331879/ Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):868-80. doi: 10.1055/s-0031-1297042. PMID: 15646371. https://pubmed.ncbi.nlm.nih.gov/15646371/ Laferrère, Blandine et al. “Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.” The Journal of clinical endocrinology and metabolism vol. 90,2 (2005): 611-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824650/ Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632578/ Rogério G. Gondo et al, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 3279–3283, https://doi.org/10.1210/jcem.86.7.7694. Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998 Jul;83(7):2355-60. https://pubmed.ncbi.nlm.nih.gov/9661608/ Emanuela Arvat, Lidia Di Vito, Barbara Maccagno, Fabio Broglio, Muni F Boghen, Romano Deghenghi, Franco Camanni, Ezio Ghigo, Effects of GHRP-2 and Hexarelin, Two Synthetic GH-Releasing Peptides, on GH, Prolactin, ACTH and Cortisol Levels in Man. Comparison with the Effects of GHRH, TRH and hCRH, Peptides, Volume 18, Issue 6, 1997, Pages 885-891, ISSN 0196-9781, https://doi.org/10.1016/S0196-9781(97)00016-8 Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30 Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
Sermorelin & GHRP-6 Blend (10mg)
Sermorelin and GHRP-6 are synthetic research peptides that both appear to interact with pituitary cells, albeit via different receptors. Sermorelin is an analog of the endogenous Growth Hormone-Releasing Hormone and is thought to act mainly at the classical GHRH receptor on anterior pituitary cells. Activating them is thought to lead to growth hormone release from pituitary cells, potentially. GHRP-6, by contrast, is classified as a growth hormone secretagogue (GHS) and appears to interact with ghrelin-sensitive receptors such as GHS-R1a, which are distinct from the GHRH receptor and may prefer partially separate intracellular signaling pathways. Activating them may also lead to growth hormone release from pituitary cells. Because these two receptor families seem to converge on the same GH-producing cells while using different upstream inputs, investigators have posited that combining Sermorelin and GHRP-6 in experimental models might provide a stronger or more nuanced stimulus to somatotroph function than either peptide alone. Chemical Makeup Other Known Titles Sermorelin: GRF 1-29 NH2 GHRP-6: SKF-110679, growth hormone-releasing hexapeptide Molecular Weight: Sermorelin:93 g/mol GHRP-6:03 g/mol Molecular Formula: Sermorelin: C149H246N44O42S GHRP-6: C46H56N12O6 Research and Clinical Studies Sermorelin & GHRP-6 Structure Sermorelin is posited to be a 29–amino acid fragment corresponding to the N-terminal portion of endogenous GHRH, with a C-terminal amidation that may help stabilize the molecule. Experimental work such as that of Clark et al. suggests that this fragment apparently retains full affinity and activation potential for pituitary GHRH receptors.(1) Consequently, this receptor activation is thought to drive cAMP-linked pathways that support growth hormone synthesis and release from pituitary cells. Thus, they commented that Sermorelin potentially “accelerates growth and increases pituitary GH content.” Research suggests that rather than being a GHRH analog, GHRP-6 appears to be a hexapeptide designed to interact with a different set of receptors on pituitary cells, referred to as ghrelin receptors. Yet, researchers such as Bowers et al. reveal that the peptide is not an analog to ghrelin, but appears derived from an opioid receptor agonist referred to as met-enkephalin.(2) The difference is that GHRP-6 is modified so that it loses opioid receptor affinity and gains ghrelin receptor affinity. Before the discovery of ghrelin receptors, these were actually termed growth hormone secretagogue 1a receptors (GHS-R1a), and the molecules that might interact with them, like GHRP-6, are suggested to be growth hormone secretagogues (GHSs). Sermorelin & GHRP-6 Affinity Towards Pituitary Cell Receptors As mentioned, Sermorelin and GHRP-6 may both interact with pituitary cells to stimulate growth hormone release, but appear to achieve that via different receptors and cellular pathways. Research by Culhane et al. suggests that Sermorelin may activate the GHRH receptors similarly to endogenous GHRH.(3) This may involve the activation of an intracellular messenger called cyclic AMP (cAMP) and the kinase PKA (protein kinase A), which together may switch on the cellular machinery that moves growth-hormone–containing vesicles to the membrane for release. On the other hand, GHRP-6 appears to target pituitary cells through the GHS-R1a receptor. Studies such as those by Yin et al. indicate that ligands of this receptor may favor activation of another messenger called phospholipase C.(4) PLC then is thought to cleave membrane PIP₂ into second messengers such as IP₃ and DAG. IP₃ may move toward intracellular calcium stores and trigger calcium release into the cytosol, while DAG remains in the membrane and potentially activates PKC (protein kinase C). Similar to PKA, PKC, in combination with the increased calcium release, may mobilize growth hormone-containing granules toward the plasma membrane of pituitary cells and promote their discharge. Sermorelin & GHRP-6 Potential for Growth Hormone Release Research on pituitary cells suggests that exposure to Sermorelin may induce an upregulation of growth hormone synthesis and release capacity. In experiments by Vittone et al., 12-hour mean growth hormone concentrations apparently rose from about 1.1 ± 0.9 µg/L to roughly 2.2 ± 1.9 µg/L, while the integrated 12-hour growth hormone output increased from around 1,114 ± 931 to about 2,032 ± 1,728 µg·min/L.(5) Further work by Khorram et al. with a slightly modified Sermorelin molecule indicates that the most pronounced potential of the peptide on growth hormone output may be exerted within the first 2 hours.(6) The researchers suggest that the 2-hour growth hormone levels appeared to rise from roughly 200–300 to about 1,100–1,600 µg·L⁻¹·min, which they described as an approximate sixfold increase. Moreover, the researchers commented that this potential may have been accompanied by an upregulation in the “levels of IGF-I (P < 0.05) and IGFBP-3 (P < 0.001), but not IGFBP-1, which remained elevated for 12 weeks.” IGF-1 stands for insulin-like growth factor-1. Peptides like these have been posited to be the main mediators of growth hormone's anabolic actions towards different cells. Growth hormone is thought to interact with growth hormone receptors on different cells and stimulate IGF-1 synthesis, which in this experiment appeared to be increased by 27–28% following the Sermorelin experimentation. Similar experiments with the ghrelin-receptor agonist GHRP-6 suggest that it may also provoke growth hormone peaks from basal values near 1–2 mU/L to around 60 mU/L, which corresponds to roughly a 30- to 50-fold increase over baseline and more than a threefold rise over usual physiological peaks of up to 20 mU/L. Researchers such as Micle et al. have interpreted these findings as a potential of GHRP-6 for strong engagement of GHS-R1a-linked signaling that drives high-amplitude secretory bursts.(7) Sermorelin & GHRP-6 Synergistic Actions The aforementioned experiment by Micle et al. also investigated the potential of GHRP-6 on growth hormone synthesis when combined with GHRH analogs. Specifically, the researchers experimented with the full-length GHRH rather than Sermorelin.(7) Nevertheless, their research suggests that the blend may lead to a peak growth hormone reaching up to 140 mU/L, roughly doubling the GHRP-6–only response of 60 mU/L and representing an approximate 6-fold increase over physiological peaks. Further research by Cordido et al. also compared the potential of GHRP-6 alone vs the synergistic potential of GHRP-6 with a GHRH analog.(8) These researchers were working with pituitary cells with much lower baseline growth hormone synthesis that was nearly undetectable. Exposure to GHRP-6 alone apparently caused an average growth hormone peak of about 6 mU/L. In contrast, exposure to a GHRH analogue alone appeared to yield a smaller growth hormone peak of roughly 2.6 mU/L, but the combination of GHRP-6 and GHRH analog led to a total peak of 16.3 mU/L, which was approximately 2.7 times the GHRP-6–only peak and 6.2 times the GHRH analog-only peak. The 12-hour growth hormone levels with GHRP-6 alone were suggested to be around 260 mU·min/L, versus 159 mU·min/L for GHRH analog, but reaching up to 729 mU·min/L when the two peptides were blended. Even though the GHRH-analog was not Sermorelin, the research suggests that a combination of GHRP-6 with a peptide like Sermorelin may induce synergistic actions on pituitary cells. The only one of these experiments to combine GHRP-6 specifically with Sermorelin was conducted by Sigalos et al.(9) The researchers combined the two peptides alongside another GHRP and their findings suggest that the blend upregulated growth hormone levels from baseline values of 160 ng/mL to roughly 250–265 ng/mL, which corresponds to an apparent 1.6-fold increase. This data further suggests that GHRP-6 and Sermorelin may exert synergistic actions, although more data is needed to evaluate their potential as a blend in laboratory research. Sermorelin & GHRP-6 blend is available for research and laboratory purposes only. Please review our Terms and Conditions before ordering. References: Clark RG, Robinson IC. Growth induced by pulsatile infusion of an amidated fragment of hGH-releasing factor in normal and GHRF-deficient rats. Nature. 1985 Mar 21-27;314(6008):281-3. doi: 10.1038/314281a0. PMID: 2858818. Bowers CY. History to the discovery of ghrelin. Methods Enzymol. 2012;514:3-32. doi: 10.1016/B978-0-12-381272-8.00001-5. PMID: 22975043. Culhane KJ, Liu Y, Cai Y, Yan EC. Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors. Front Pharmacol. 2015 Nov 5;6:264. doi: 10.3389/fphar.2015.00264. PMID: 26594176; PMCID: PMC4633518. Yin Y, Li Y, Zhang W. The growth hormone secretagogue receptor: its intracellular signaling and regulation. Int J Mol Sci. 2014 Mar 19;15(3):4837-55. doi: 10.3390/ijms15034837. PMID: 24651458; PMCID: PMC3975427. Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RG. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997 Jan;46(1):89-96. doi: 10.1016/s0026-0495(97)90174-8. PMID: 9005976. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997 May;82(5):1472-9. doi: 10.1210/jcem.82.5.3943. PMID: 9141536. Micic D, Popovic V, Kendereski A, Macut D, Casanueva FF, Dieguez C. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood. Clin Endocrinol (Oxf). 1995 Feb;42(2):191-4. doi: 10.1111/j.1365-2265.1995.tb01861.x. PMID: 7734029. Cordido F, Peñalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab. 1993 Apr;76(4):819-23. doi: 10.1210/jcem.76.4.8473389. PMID: 8473389. Sigalos JT, Pastuszak AW, Allison A, Ohlander SJ, Herati A, Lindgren MC, Lipshultz LI. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017 Nov;11(6):1752-1757. doi: 10.1177/1557988317718662. Epub 2017 Aug 22. PMID: 28830317; PMCID: PMC5675260. Dr. MarinovDr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.